|
1
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Neill JP and Shaha AR: Anaplastic
thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kojic SL, Strugnell SS and Wiseman SM:
Anaplastic thyroid cancer: A comprehensive review of novel therapy.
Expert Rev Anticancer Ther. 11:387–402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang HM, Huang YW, Huang JS, Wang CH, Kok
VC, Hung CM, Chen HM and Tzen CY: Anaplastic carcinoma of the
thyroid arising more often from follicular carcinoma than papillary
carcinoma. Ann Surg Oncol. 14:3011–3018. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quiros RM, Ding HG, Gattuso P, Prinz RA
and Xu X: Evidence that one subset of anaplastic thyroid carcinomas
are derived from papillary carcinomas due to BRAF and p53
mutations. Cancer. 103:2261–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Z, Hou P, Ji M, Guan H, Studeman K,
Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent
genetic alterations in receptor tyrosine kinases and
phosphatidylinositol 3-kinase/akt and mitogen-activated protein
kinase pathways in anaplastic and follicular thyroid cancers. J
Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Russo D, Damante G, Puxeddu E, Durante C
and Filetti S: Epigenetics of thyroid cancer and novel therapeutic
targets. J Mol Endocrinol. 46:R73–R81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tallini G, Garcia-Rostan G, Herrero A,
Zelterman D, Viale G, Bosari S and Carcangiu ML: Downregulation of
p27KIP1 and Ki67/Mib1 labeling index support the
classification of thyroid carcinoma into prognostically relevant
categories. Am J Surg Pathol. 23:678–685. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pita JM, Figueiredo IF, Moura MM, Leite V
and Cavaco BM: Cell cycle deregulation and TP53 and RAS mutations
are major events in poorly differentiated and undifferentiated
thyroid carcinomas. J Clin Endocrinol Metab. 99:E497–E507.
2014.PubMed/NCBI
|
|
12
|
Gucký T, Jorda R, Zatloukal M, Bazgier V,
Berka K, Řezníčková E, Béres T, Strnad M and Kryštof V: A novel
series of highly potent 2,6,9-trisubstituted purine
cyclin-dependent kinase inhibitors. J Med Chem. 56:6234–6247. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hersey P, Bastholt L, Chiarion-Sileni V,
Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I,
Robert C, et al: Small molecules and targeted therapies in distant
metastatic disease. Ann Oncol. 20(Suppl 6): vi35–vi40. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haider C, Grubinger M, Řezníčková E, Weiss
TS, Rotheneder H, Miklos W, Berger W, Jorda R, Zatloukal M, Gucky
T, et al: Novel inhibitors of cyclin-dependent kinases combat
hepatocellular carcinoma without inducing chemoresistance. Mol
Cancer Ther. 12:1947–1957. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pilli T, Prasad KV, Jayarama S, Pacini F
and Prabhakar BS: Potential utility and limitations of thyroid
cancer cell lines as models for studying thyroid cancer. Thyroid.
19:1333–1342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schweppe RE, Klopper JP, Korch C,
Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland
JA, Smallridge RC, et al: Deoxyribonucleic acid profiling analysis
of 40 human thyroid cancer cell lines reveals cross-contamination
resulting in cell line redundancy and misidentification. J Clin
Endocrinol Metab. 93:4331–4341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baldan F, Lavarone E, Di Loreto C, Filetti
S, Russo D, Damante G and Puppin C: Histone post-translational
modifications induced by histone deacetylase inhibition in
transcriptional control units of NIS gene. Mol Biol Rep.
41:5257–5265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Papewalis C, Wuttke M, Schinner S,
Willenberg HS, Baran AM, Scherbaum WA and Schott M: Role of the
novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid
cancer. Horm Metab Res. 41:752–756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou TC and Talalay P: Analysis of
combined drug effects: A new look at a very old problem. Trends
Pharmacol Sci. 4:450–454. 1983. View Article : Google Scholar
|
|
21
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Denaro N, Nigro CL, Russi EG and Merlano
MC: The role of chemotherapy and latest emerging target therapies
in anaplastic thyroid cancer. Onco Targets Ther. 9:1231–1241. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schlumberger M, Lacroix L, Russo D,
Filetti S and Bidart JM: Defects in iodide metabolism in thyroid
cancer and implications for the follow-up and treatment of
patients. Nat Clin Pract Endocrinol Metab. 3:260–269. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Senderowicz AM: Targeting cell cycle and
apoptosis for the treatment of human malignancies. Curr Opin Cell
Biol. 16:670–678. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S, Wuu J, Savas L, Patwardhan N and
Khan A: The role of cell cycle regulatory proteins, cyclin D1,
cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol.
29:1304–1309. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elisei R, Shiohara M, Koeffler HP and
Fagin JA: Genetic and epigenetic alterations of the
cyclin-dependent kinase inhibitors p15INK4b and
p16INK4a in human thyroid carcinoma cell lines and
primary thyroid carcinomas. Cancer. 83:2185–2193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rocha AS, Paternot S, Coulonval K, Dumont
JE, Soares P and Roger PP: Cyclic AMP inhibits the proliferation of
thyroid carcinoma cell lines through regulation of CDK4
phosphorylation. Mol Biol Cell. 19:4814–4825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li F, Zhao C and Wang L:
Molecular-targeted agents combination therapy for cancer:
Developments and potentials. Int J Cancer. 134:1257–1269. 2014.
View Article : Google Scholar
|
|
29
|
Carracedo A, Baselga J and Pandolfi PP:
Deconstructing feedback-signaling networks to improve anticancer
therapy with mTORC1 inhibitors. Cell Cycle. 7:3805–3809. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perri F, Lorenzo GD, Scarpati GD and
Buonerba C: Anaplastic thyroid carcinoma: A comprehensive review of
current and future therapeutic options. World J Clin Oncol.
2:150–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
